General Information of Drug (ID: DM3F7SD)

Drug Name
PS-777621 Drug Info
Synonyms PS-777621; CHEMBL318055; BDBM50146527; (S)-3-(S)-Hydroxy-6-methyl-4-{(S)-3-methyl-2-[2-(naphthalen-2-yloxy)-acetylamino]-pentanoylamino}-heptanoic acid butylamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44330683
TTD Drug ID
DM3F7SD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9353089, 135 DMWG98Z N. A. N. A. Patented [2]
US9353089, 330 DMK02LS N. A. N. A. Patented [2]
US9353089, 327 DMB4MJ0 N. A. N. A. Patented [2]
Pepstatin DM9S1EA Malaria 1F40-1F45 Terminated [3]
Leupeptin DMU075F Malaria 1F40-1F45 Investigative [3]
E-64 DMMOPAK Discovery agent N.A. Investigative [4]
KNI-10006 DMMISH6 Discovery agent N.A. Investigative [5]
PS-662477 DMT4YFR Discovery agent N.A. Investigative [6]
KNI-10740 DMPWY6H Discovery agent N.A. Investigative [5]
KNI-10265 DMQLB3T Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pepstatin DM9S1EA Malaria 1F40-1F45 Terminated [3]
Leupeptin DMU075F Malaria 1F40-1F45 Investigative [3]
E-64 DMMOPAK Discovery agent N.A. Investigative [4]
KNI-10006 DMMISH6 Discovery agent N.A. Investigative [8]
SC-5003 DM2DU80 Discovery agent N.A. Investigative [9]
L-mannitol derivative DMK12C0 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Plasmepsin 1 (Malaria PLA1) TTH9VL3 PLM1_PLAFA Inhibitor [1]
Plasmodium Plasmepsin 2 (Malaria PLA2) TTXMNHO PLM2_PLAFA Inhibitor [1]

References

1 High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9.
2 Compositions and methods for the treatment of malaria. US9353089.
3 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
4 Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8.
5 Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
6 Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.
7 Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60.
8 alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
9 Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.
10 Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem. 2005 Sep 22;48(19):6090-106.